## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the abstract; no access to full methods, figures, tables, or supplementary data
- **Shared manuscript claim summary** The authors report a computational analysis of 46 experimentally reported single-nucleotide polymorphisms (SNPs) in the E2F1 gene, identifying nine predicted deleterious variants, four of which (L206W, R232C, I254T, A267T) are claimed to be highly destabilizing. Molecular docking and simulation are used to compare wild-type and mutant E2F1 binding to RB, with reported docking scores and binding free energies indicating reduced affinity for all four mutants. The authors claim this is the first extensive analysis of E2F1 mutations and propose candidate mutations for validation and therapeutic targeting.
- **Visible evidence base** Abstract text only; no methods, figures, tables, or supplementary information provided
- **Missing materials affecting confidence** Full manuscript, methods details, validation datasets, structural coordinates, simulation parameters, statistical analyses, and any experimental corroboration

## Reviewer
- **Overall assessment** The abstract presents a straightforward computational pipeline for assessing the impact of E2F1 SNPs on RB binding. The logic from SNP selection to deleterious prediction to structural and dynamical analysis is coherent. However, the evidence base is limited to summary statistics and scores, with no methodological detail or validation data. The central claim that these mutations "disrupt" the E2F1-RB interaction rests entirely on in silico predictions, and the abstract does not provide sufficient information to assess the robustness, reproducibility, or biological relevance of the findings. The novelty claim is plausible but unverifiable from the abstract alone.
- **Who would be interested in the results, and why** Researchers in cancer genetics, computational biology, and structural bioinformatics would be the primary audience. Those studying cell cycle regulation, E2F/RB pathway dysregulation in cancer, or developing targeted therapies against transcription factor complexes may find the candidate mutations useful for further experimental validation. Clinicians interested in germline or somatic variants in E2F1 as potential biomarkers might also take note, though the translational relevance is not established.
- **Major strengths** The study addresses a biologically important interaction (E2F1-RB) with clear relevance to cancer. The workflow is logical and integrates multiple computational tools, from SNP effect prediction to docking and molecular dynamics. The identification of four specific mutations with consistent trends across docking scores and binding free energies provides a focused set of candidates for downstream studies. The abstract is concise and the quantitative results are clearly presented.
- **Major Concerns** 
  - R1-M1: The abstract provides no methodological details, making it impossible to evaluate the quality of the computational predictions, the choice of tools, the parameters used, or the statistical significance of the reported differences.
  - R1-M2: The claim that the mutations "disrupt" the E2F1-RB interaction is based solely on predicted binding scores and free energy calculations, with no experimental validation. The magnitude of the reported changes may or may not be biologically meaningful, and this cannot be assessed without error estimates or comparison to known functional thresholds.
  - R1-M3: The novelty claim ("first to extensively analyze E2F1 gene mutations") is unverifiable from the abstract and is not supported by any literature comparison.
  - R1-M4: The abstract does not state how the 46 SNPs were selected, whether they are germline or somatic, or whether they are derived from cancer cohorts, which limits the interpretability of the results.
- **Minor Comments** 
  - R1-m1: The abstract does not specify the software or algorithms used for deleteriousness prediction, docking, or simulation, which should be stated for reproducibility.
  - R1-m2: The units and meaning of the docking score (-242 kcal/mol) are unusual; typical docking scores are not reported in kcal/mol in most docking software, and this should be clarified.
  - R1-m3: The abstract does not report any measures of variance, confidence intervals, or replicate numbers for the simulation results.
  - R1-m4: The phrase "highly destabilizing" is used without defining a threshold or comparing to known stabilizing/destabilizing mutations in other proteins.
  - R1-m5: The abstract does not mention whether the four mutations are located in known functional domains of E2F1, which would strengthen the biological interpretation.
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M4. Without methodological transparency, error estimates, and a clear definition of the SNP source population, the central claims cannot be evaluated.
- **Assessment against Nature-style criteria** 
  - Originality: The approach is not novel in itself, as similar computational pipelines are common. The specific focus on E2F1 SNPs may be new, but this is not established from the abstract.
  - Scientific importance: The E2F1-RB interaction is important in cancer biology, and identifying deleterious variants could have translational value. However, the importance of these specific findings is not demonstrated.
  - Interdisciplinary readership: The work sits at the intersection of cancer genetics and structural biology, which could attract a broad readership, but the abstract is too technical and lacks context for nonspecialists.
  - Technical soundness: Cannot be assessed from the abstract. The reported scores and energies are presented without methodological context or statistical support.
  - Readability for nonspecialists: The abstract is accessible in structure but assumes familiarity with computational mutation analysis and molecular simulation terminology. The biological significance is not framed for a general audience.
- **Recommendation posture** Currently not established from the provided evidence. The abstract alone does not provide sufficient methodological detail, validation, or context to support the claims. A full manuscript with detailed methods, error analysis, and ideally some experimental or literature-based validation would be required to assess whether the case is made.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Technical soundness
- **Claim pointer** The authors claim that four mutations (L206W, R232C, I254T, A267T) are "highly destabilizing" and that molecular docking and simulation reveal altered dynamics and reduced binding affinity.
- **Evidence pointer** Abstract; location not provided
- **Concern** The abstract provides no information on the computational methods used, including the names and versions of prediction tools, docking software, force fields, simulation lengths, or analysis protocols. Without this, the results cannot be reproduced or independently evaluated.
- **Why it matters** Reproducibility is a core requirement for computational studies. The absence of methodological detail means that the reported scores and energies could be artifacts of specific tool choices or parameter settings.
- **Resolution test** The full manuscript must include a detailed methods section, and ideally a supplementary file with input files, parameters, and output data. The authors should also state whether the predictions were cross-validated with multiple tools or approaches.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence strength
- **Claim pointer** The authors claim that the mutations "disrupt" the E2F1-RB protein interaction, based on docking scores and binding free energies.
- **Evidence pointer** Abstract; location not provided
- **Concern** The reported differences in docking scores (from -242 to -217 to -220 kcal/mol) and binding free energies (from -64.89 to -45.90 to -61.22 kcal/mol) are presented without any error estimates, statistical tests, or comparison to known functional thresholds. It is unclear whether these differences are significant or biologically relevant.
- **Why it matters** The central conclusion of the study rests on the interpretation of these quantitative differences. Without uncertainty measures or benchmarks, the claim of "disruption" is not supported.
- **Resolution test** The authors should provide standard deviations or confidence intervals from replicate simulations, and compare the predicted binding affinities to experimentally known E2F1-RB binding constants or to a set of neutral variants as a control.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** No
- **Axis** Originality
- **Claim pointer** The authors state, "Our study is the first to extensively analyze E2F1 gene mutations."
- **Evidence pointer** Abstract; location not provided
- **Concern** No literature comparison is provided to support the claim of being "first." It is possible that other studies have analyzed E2F1 variants, and the abstract does not demonstrate a gap in the literature.
- **Why it matters** Novelty claims are important for positioning the work, but unsupported claims can undermine credibility.
- **Resolution test** The full manuscript should include a literature review demonstrating that no prior study has performed a comparable analysis, and the claim should be tempered or supported with specific citations.

- **Concern ID** R1-M4
- **Severity** Major
- **Blocking** Yes
- **Axis** Context and interpretability
- **Claim pointer** The authors state that "experimentally reported SNPs in E2F1" were analyzed.
- **Evidence pointer** Abstract; location not provided
- **Concern** The abstract does not specify the source of the 46 SNPs, whether they are germline or somatic, which cancer types they are associated with, or how they were curated. This information is essential for interpreting the relevance of the findings.
- **Why it matters** Without knowing the population and disease context, the translational implications of the identified mutations cannot be assessed. The relevance to cancer therapeutics is claimed but not contextualized.
- **Resolution test** The full manuscript should describe the SNP source database, inclusion criteria, and any cancer type associations. The authors should also discuss whether the four prioritized mutations have been observed in patient cohorts.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Reproducibility
- **Affected element** Methods
- **Evidence pointer** Abstract; location not provided
- **Issue** The abstract does not name any of the software tools used for prediction, docking, or simulation.
- **Required correction** The full manuscript must list all tools and versions, and ideally provide access to configuration files or scripts.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Technical clarity
- **Affected element** Results reporting
- **Evidence pointer** Abstract; location not provided
- **Issue** The docking score is reported in kcal/mol, which is unconventional for most docking software (e.g., AutoDock reports in kcal/mol, but many others use arbitrary units). This needs clarification.
- **Required correction** Specify the docking software and the meaning of the reported score, or convert to a standard unit if applicable.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Statistical reporting
- **Affected element** Results
- **Evidence pointer** Abstract; location not provided
- **Issue** No measures of variance or replicate numbers are reported for the simulation-derived free energies.
- **Required correction** Provide standard deviations, standard errors, or confidence intervals for all reported energies, and state the number of independent simulations.

- **Concern ID** R1-m4
- **Severity** Minor
- **Axis** Terminology
- **Affected element** Results interpretation
- **Evidence pointer** Abstract; location not provided
- **Issue** The term "highly destabilizing" is used without a defined threshold or comparison to a reference set.
- **Required correction** Define the criteria for "highly destabilizing" and provide context, such as comparison to known benign variants or experimental stability data.

- **Concern ID** R1-m5
- **Severity** Minor
- **Axis** Biological interpretation
- **Affected element** Results discussion
- **Evidence pointer** Abstract; location not provided
- **Issue** The abstract does not state whether the four mutations are located in functional domains of E2F1, such as the DNA-binding or RB-binding domains.
- **Required correction** Include domain mapping information and discuss the structural context of the mutations in the full manuscript.

## Risk / unsupported claims
- The claim that the four mutations "disrupt" the E2F1-RB interaction is unsupported without experimental validation or benchmarked thresholds for binding affinity changes.
- The claim of being "first" to extensively analyze E2F1 mutations is unverifiable from the abstract and lacks literature support.
- The biological and clinical relevance of the identified mutations is not established, as no patient cohort data or functional assays are referenced.
- The quantitative results (docking scores and binding free energies) are presented without error estimates, making their significance unassessable.
- The selection criteria for the 46 SNPs and the source of these variants are not described, limiting the interpretability of the study.